

COMPLETE LISTING OF THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in this application.

1. - 30. (Cancelled)

31. (Previously Presented) A pharmaceutical composition comprising at least one modified mRNA that encodes at least one polypeptide and a pharmaceutically compatible carrier and/or vehicle, wherein said modified mRNA encoding the polypeptide has been stabilized by increasing its Guanine/Cytosine (G/C) content relative to that of a wild type mRNA encoding the polypeptide, and wherein the polypeptide is a human tumour antigen.

32. (Currently amended) The pharmaceutical composition according to claim 31, wherein the G/C content of the modified mRNA is increased ~~at least 15%~~ at least 7% relative to that of a wild type mRNA encoding the tumour antigen.

33. (Previously Presented) The pharmaceutical composition according to claim 31, wherein the modified mRNA encoding the human tumour antigen comprises a sequence wherein at least one codon of a wild type sequence recognized by a rare cellular tRNA is replaced with a codon recognized by an abundant cellular tRNA, and wherein said rare cellular tRNA and said abundant cellular tRNA recognize the same amino acid.

34. (Previously Presented) The pharmaceutical composition according to claim 33, wherein the modified mRNA encoding the peptide or polypeptide comprises a maximum G/C content and a maximum number of codons recognized by abundant tRNAs.

35. (Previously Presented) The pharmaceutical composition of claim 31 wherein the modified mRNA further encodes a secretory leader.

36. (Previously Presented) The pharmaceutical composition of claim 31 which is formulated for injection.

37. (new) The pharmaceutical composition according to claim 32, wherein the G/C content of the modified mRNA is increased at least 15% relative to that of a wild type mRNA encoding the tumour antigen.